Upstream Bio, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 11, 2026, covering the fiscal quarter ended June 30, 2026.

Key Highlights

  • Share count: As of August 4, 2026, Upstream Bio had 54,771,041 shares of common stock, $0.001 par value per share, outstanding.
  • Company stage: The company describes itself as a clinical-stage biopharmaceutical company with a limited operating history.
  • Single product candidate: Verekitug is the company's only product candidate, according to the filing.
  • Target indications: Verekitug is being developed for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
  • Financial losses: The company disclosed that it "has incurred significant financial losses since our inception and anticipates that we will continue to incur significant financial losses for the foreseeable future."
  • Filer status: Upstream Bio is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Upstream Bio's Q2 2026 Quarterly Disclosure: Verekitug Development and Financial Position

Upstream Bio, Inc. (NASDAQ:UPB), headquartered at 890 Winter Street, Suite 200, Waltham, MA 02451, submitted its Form 10-Q for the quarterly period ended June 30, 2026. The filing, assigned Commission File Number 001-42366, is listed on The Nasdaq Global Select Market under the trading symbol UPB. The registrant confirmed it has filed all required reports during the preceding 12 months and is not a shell company.

According to the filing, verekitug is the company's sole product candidate, and the company acknowledged its dependence on "a third party having accurately generated, collected and reported data from certain preclinical studies that were previously conducted for verekitug." The filing also disclosed that additional funding will be required to finance operations, and that an inability to raise capital "could be forced to delay, reduce or eliminate our product development programs or commercialization efforts," according to the company's own risk factor disclosures.

The filing contains forward-looking statements relating to clinical trial initiation and progress, regulatory submissions including Investigational New Drug applications, manufacturing, commercialization, and intellectual property. The company states that such forward-looking statements are covered by safe harbor provisions and are subject to known and unknown risks and uncertainties, as described in the filing's Risk Factors section. Investors are cautioned in the filing not to unduly rely on these statements.

What Was Disclosed

Upstream Bio filed its Q2 2026 quarterly report disclosing its status as a clinical-stage company with one product candidate, verekitug, targeted at three indications. The filing noted ongoing financial losses and the need for additional future capital.